Intervention Review

Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)

  1. Katrina Williams1,2,3,*,
  2. Amanda Brignell1,
  3. Melinda Randall1,
  4. Natalie Silove4,
  5. Philip Hazell5

Editorial Group: Cochrane Developmental, Psychosocial and Learning Problems Group

Published Online: 20 AUG 2013

Assessed as up-to-date: 7 AUG 2013

DOI: 10.1002/14651858.CD004677.pub3

How to Cite

Williams K, Brignell A, Randall M, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD004677. DOI: 10.1002/14651858.CD004677.pub3.

Author Information

  1. 1

    University of Melbourne, The Royal Children's Hospital, Department of Paediatrics, Parkville, Victoria, Australia

  2. 2

    The Royal Children's Hospital, 3W Clinical Offices, Parkville, Victoria, Australia

  3. 3

    Murdoch Childrens Research Institute, Parkville, Victoria, Australia

  4. 4

    The Children's Hospital at Westmead, Child Development Unit, Westmead, New South Wales, Australia

  5. 5

    Sydney Medical School, Discipline of Psychiatry, Concord West, New South Wales, Australia

*Katrina Williams, katrina.williams@rch.org.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 20 AUG 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary

Background

Autism spectrum disorders (ASD) are characterised by abnormalities in social interaction and communication skills, as well as stereotypic behaviours and restricted activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are prescribed for the treatment of conditions often comorbid with ASD such as depression, anxiety and obsessive-compulsive behaviours.

Objectives

To determine if treatment with an SSRI:
1. improves the core features of autism (social interaction, communication and behavioural problems);
2. improves other non-core aspects of behaviour or function such as self-injurious behaviour;
3. improves the quality of life of adults or children and their carers;
4. has short- and long-term effects on outcome;
5. causes harm.

Search methods

We searched the following databases up until March 2013: CENTRAL, Ovid MEDLINE, Embase, CINAHL, PsycINFO, ERIC and Sociological Abstracts. We also searched ClinicalTrials.gov and the International Clinical Trials Registry Platform (ICTRP). This was supplemented by searching reference lists and contacting known experts in the field.

Selection criteria

Randomised controlled trials (RCTs) of any dose of oral SSRI compared with placebo, in people with ASD.

Data collection and analysis

Two authors independently selected studies for inclusion, extracted data and appraised each study's risk of bias.

Main results

Nine RCTs with a total of 320 participants were included. Four SSRIs were evaluated: fluoxetine (three studies), fluvoxamine (two studies), fenfluramine (two studies) and citalopram (two studies). Five studies included only children and four studies included only adults. Varying inclusion criteria were used with regard to diagnostic criteria and intelligence quotient of participants. Eighteen different outcome measures were reported. Although more than one study reported data for Clinical Global Impression (CGI) and obsessive-compulsive behaviour (OCB), different tool types or components of these outcomes were used in each study. As such, data were unsuitable for meta-analysis, except for one outcome (proportion improvement). One large, high-quality study in children showed no evidence of positive effect of citalopram. Three small studies in adults showed positive outcomes for CGI and OCB; one study showed improvements in aggression, and another in anxiety.

Authors' conclusions

There is no evidence of effect of SSRIs in children and emerging evidence of harm. There is limited evidence of the effectiveness of SSRIs in adults from small studies in which risk of bias is unclear.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary

Selective serotonin reuptake inhibitors for treating people with autism spectrum disorders

Autism spectrum disorders (ASD) are characterised by problems with social interaction and communication, as well as repetitive behaviours and limited activities and interests. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressants that are sometimes given to reduce anxiety or obsessive-compulsive behaviours. We found nine trials, involving 320 people, which evaluated four SSRIs: fluoxetine, fluvoxamine, fenfluramine and citalopram. Five studies included only children and four studies included only adults. One trial enrolled 149 children, but the other trials were much smaller. We found no trials that evaluated sertraline, paroxetine or escitalopram. There is no evidence to support the use of SSRIs to treat autism in children. There is limited evidence, which is not yet sufficiently robust, to suggest effectiveness of SSRIs in adults with autism. Treatment with an SSRI may cause side effects. Decisions about the use of SSRIs for established clinical indications that may co-occur with autism, such as obsessive-compulsive disorder and depression in adults or children, and anxiety in adults, should be made on a case-by-case basis.